Patient Resources
At Centessa, we are committed to developing innovative therapies that have the potential to improve the lives of individuals living with excessive daytime sleepiness, impaired attention, cognitive deficits and fatigue associated with a broad spectrum of neurological, neurodegenerative and neuropsychiatric disorders.
We recognize how challenging it can be to live with these conditions—or to support someone who does. Whether you’ve recently been diagnosed, are caring for a loved one, or are simply seeking to better understand these disorders, you are not alone.
In addition to advancing our clinical work, we are equally dedicated to supporting the broader community through education, advocacy and access to resources for patients and families.
Sleep-Wake Disorders
Narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) are chronic neurological conditions that interfere with the brain’s ability to regulate sleep and wakefulness. These disorders can have a significant impact on daily life—making even routine tasks feel overwhelming.
We are at the forefront of developing an orexin receptor 2 (OX2R) agonist for the potential treatment of NT1, NT2 and IH. Our OX2R agonist product candidate is designed to mimic the body’s natural neuropeptide orexin (also called hypocretin) by activating orexin receptors that are abundantly expressed throughout the brain to produce signals that keep us awake.
If you or a loved one have been diagnosed with one of these sleep-wake disorders and are seeking more information, we invite you to explore our downloadable brochure, which provides an overview of Centessa’s scientific approach and explores the role orexin may play in regulating sleep and wakefulness.
Clinical Trials